Skip to content
Evigrade
CriticalSecond-generation systemic triazole antifungal×Second-generation systemic triazole antifungal

Updated · Methodology

Mechanism

Posaconazole is a strong inhibitor of the enzyme CYP3A4 (posaconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, and posaconazole label, US Food and Drug Administration, FDA), and isavuconazole is a sensitive substrate of this enzyme (isavuconazole label, FDA). The two drugs have not been studied together, and the documents give no figures for this pair. Ketoconazole, another strong CYP3A4 inhibitor, increased isavuconazole exposure (area under the curve, AUC) by 422%, and lopinavir with ritonavir by 96% (isavuconazole SmPC, EMA). In the other direction, glucuronidation (UGT enzymes) is the main route of posaconazole metabolism, and the efflux transporter P-gp carries posaconazole out of cells, so inhibitors of these pathways may raise its levels (posaconazole SmPC and label, EMA and FDA). Isavuconazole is a mild inhibitor of both UGT and P-gp (isavuconazole SmPC and label, EMA and FDA). There are no measurements for this direction. According to the posaconazole SmPC, CYP450 inhibitors do not appear to change posaconazole levels (EMA).

Symptoms

Higher isavuconazole levels may bring more adverse reactions (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). At three times the usual maintenance dose, headache, dizziness, tingling, numbness in the mouth, sleepiness, poor attention, taste disturbance, dry mouth, diarrhoea, vomiting, flushing, anxiety, restlessness, palpitations, fast heart rate, sensitivity to light and joint pain were more frequent (isavuconazole SmPC, EMA, and isavuconazole label, US Food and Drug Administration, FDA). Both drugs can cause liver injury, including liver failure with fatal outcomes (posaconazole and isavuconazole labels, FDA). QT prolongation and torsade de pointes have been reported with posaconazole (posaconazole label, FDA), while isavuconazole shortens the QT interval, more so at higher concentrations (isavuconazole SmPC, EMA). The documents do not say how these effects combine.

Management

The US isavuconazole label contraindicates the combination: it contraindicates all strong CYP3A4 inhibitors. According to its own documents, posaconazole is a strong CYP3A4 inhibitor (isavuconazole and posaconazole labels, US Food and Drug Administration, FDA, and posaconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). The European isavuconazole SmPC is less strict and does not name posaconazole: among strong CYP3A4 inhibitors it contraindicates only ketoconazole. With the others, the SmPC keeps the isavuconazole dose unchanged but advises caution, because adverse reactions may increase (isavuconazole SmPC, EMA). According to the European posaconazole SmPC, posaconazole should be used with drugs metabolised by CYP3A4 only under specific circumstances (posaconazole SmPC, EMA). No document gives a waiting time between stopping one drug and starting the other, only mean half-lives: 130 hours for isavuconazole (FDA) and 29 hours for posaconazole tablets, range 26–31 hours (posaconazole SmPC, EMA). Evaluate liver tests before and during posaconazole treatment (posaconazole SmPC, EMA) and at the start of and during isavuconazole treatment (isavuconazole label, FDA). If signs of liver disease appear, stop isavuconazole if they may be due to it (FDA), and consider stopping posaconazole (EMA, FDA). In people with an allergy to other azole antifungals, the US label contraindicates posaconazole and the European SmPC advises caution (posaconazole label and SmPC, FDA and EMA). In this case, prescribe isavuconazole with caution and watch for signs of an allergic reaction (isavuconazole SmPC and label, EMA and FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Isavuconazole

Other interactions with Posaconazole